Concepts (260)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vascular Stiffness | 9 | 2023 | 79 | 4.500 |
Why?
|
| Hypertension | 17 | 2024 | 1591 | 4.160 |
Why?
|
| Blood Pressure | 19 | 2024 | 1568 | 3.890 |
Why?
|
| Dyslipidemias | 12 | 2023 | 241 | 2.910 |
Why?
|
| Cardiovascular Diseases | 13 | 2024 | 2224 | 1.880 |
Why?
|
| Adipokines | 3 | 2017 | 97 | 1.620 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 5 | 2022 | 55 | 1.490 |
Why?
|
| Pulse Wave Analysis | 7 | 2023 | 49 | 1.430 |
Why?
|
| Aortic Coarctation | 2 | 2023 | 105 | 1.400 |
Why?
|
| Obesity | 9 | 2023 | 2904 | 1.390 |
Why?
|
| Hypolipidemic Agents | 3 | 2016 | 187 | 1.350 |
Why?
|
| American Heart Association | 9 | 2024 | 287 | 1.340 |
Why?
|
| Hypertrophy, Left Ventricular | 4 | 2023 | 113 | 1.270 |
Why?
|
| Echocardiography | 4 | 2019 | 1228 | 1.190 |
Why?
|
| Lipids | 4 | 2020 | 654 | 1.170 |
Why?
|
| Rheumatic Heart Disease | 2 | 2018 | 44 | 1.090 |
Why?
|
| Atherosclerosis | 3 | 2023 | 912 | 1.020 |
Why?
|
| Mass Screening | 4 | 2021 | 1552 | 0.990 |
Why?
|
| Pediatric Obesity | 3 | 2020 | 376 | 0.950 |
Why?
|
| Adolescent | 38 | 2024 | 32767 | 0.940 |
Why?
|
| Environmental Exposure | 2 | 2024 | 290 | 0.900 |
Why?
|
| Pediatrics | 5 | 2021 | 1186 | 0.850 |
Why?
|
| Ductus Arteriosus | 1 | 2023 | 65 | 0.840 |
Why?
|
| Hyperinsulinism | 1 | 2023 | 86 | 0.830 |
Why?
|
| Hemodynamics | 4 | 2017 | 949 | 0.800 |
Why?
|
| Body Mass Index | 7 | 2021 | 2232 | 0.800 |
Why?
|
| Child | 34 | 2024 | 30559 | 0.800 |
Why?
|
| Life Style | 3 | 2021 | 618 | 0.790 |
Why?
|
| Insulin Resistance | 3 | 2023 | 732 | 0.790 |
Why?
|
| Blood Pressure Determination | 2 | 2024 | 114 | 0.780 |
Why?
|
| Aorta | 3 | 2023 | 670 | 0.770 |
Why?
|
| Lipid Metabolism Disorders | 1 | 2021 | 5 | 0.760 |
Why?
|
| Risk Factors | 22 | 2024 | 17888 | 0.740 |
Why?
|
| Metabolic Syndrome | 4 | 2021 | 369 | 0.720 |
Why?
|
| Hyperglycemia | 1 | 2023 | 337 | 0.700 |
Why?
|
| Referral and Consultation | 2 | 2016 | 931 | 0.660 |
Why?
|
| Nutrition Surveys | 2 | 2018 | 317 | 0.650 |
Why?
|
| Lead | 1 | 2018 | 44 | 0.620 |
Why?
|
| Manometry | 1 | 2017 | 72 | 0.600 |
Why?
|
| Child of Impaired Parents | 1 | 2017 | 16 | 0.580 |
Why?
|
| Healthy Lifestyle | 1 | 2016 | 42 | 0.540 |
Why?
|
| Aorta, Thoracic | 1 | 2021 | 534 | 0.540 |
Why?
|
| Cross-Sectional Studies | 9 | 2019 | 4492 | 0.540 |
Why?
|
| Heart Defects, Congenital | 2 | 2023 | 1795 | 0.530 |
Why?
|
| Male | 45 | 2024 | 128315 | 0.530 |
Why?
|
| Body Weight | 1 | 2020 | 1307 | 0.520 |
Why?
|
| Office Visits | 1 | 2016 | 92 | 0.510 |
Why?
|
| Humans | 62 | 2024 | 270740 | 0.510 |
Why?
|
| Models, Econometric | 1 | 2015 | 14 | 0.500 |
Why?
|
| Longitudinal Studies | 6 | 2023 | 2057 | 0.490 |
Why?
|
| Population Surveillance | 1 | 2018 | 647 | 0.490 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2014 | 14 | 0.490 |
Why?
|
| Cardiomyopathy, Hypertrophic | 2 | 2016 | 169 | 0.480 |
Why?
|
| Female | 43 | 2024 | 148940 | 0.470 |
Why?
|
| Markov Chains | 1 | 2015 | 185 | 0.470 |
Why?
|
| Cholesterol Ester Transfer Proteins | 2 | 2011 | 39 | 0.460 |
Why?
|
| Young Adult | 13 | 2023 | 22251 | 0.460 |
Why?
|
| Heart Rate | 1 | 2017 | 742 | 0.460 |
Why?
|
| Biomarkers | 10 | 2019 | 5051 | 0.460 |
Why?
|
| Accessory Atrioventricular Bundle | 1 | 2012 | 8 | 0.430 |
Why?
|
| Primary Prevention | 1 | 2014 | 231 | 0.430 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2013 | 47 | 0.420 |
Why?
|
| Drug Prescriptions | 1 | 2015 | 311 | 0.410 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2019 | 824 | 0.410 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2012 | 25 | 0.410 |
Why?
|
| Electronic Health Records | 2 | 2017 | 850 | 0.410 |
Why?
|
| Ventricular Fibrillation | 1 | 2012 | 59 | 0.400 |
Why?
|
| Carotid Artery Diseases | 1 | 2013 | 176 | 0.390 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2012 | 246 | 0.390 |
Why?
|
| Incidence | 7 | 2021 | 5824 | 0.380 |
Why?
|
| Diabetes Mellitus | 2 | 2017 | 1024 | 0.380 |
Why?
|
| Medication Adherence | 1 | 2016 | 513 | 0.370 |
Why?
|
| Antihypertensive Agents | 3 | 2024 | 432 | 0.370 |
Why?
|
| Triglycerides | 3 | 2020 | 611 | 0.360 |
Why?
|
| United States | 14 | 2024 | 15861 | 0.360 |
Why?
|
| Health Policy | 1 | 2013 | 278 | 0.350 |
Why?
|
| Tachycardia, Ventricular | 1 | 2012 | 202 | 0.340 |
Why?
|
| Prevalence | 7 | 2018 | 3404 | 0.340 |
Why?
|
| Practice Guidelines as Topic | 4 | 2021 | 2400 | 0.330 |
Why?
|
| Sex Factors | 4 | 2020 | 2184 | 0.320 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2009 | 89 | 0.320 |
Why?
|
| Multivariate Analysis | 6 | 2017 | 4328 | 0.310 |
Why?
|
| Cardiology | 2 | 2024 | 511 | 0.300 |
Why?
|
| Arterial Pressure | 2 | 2019 | 106 | 0.300 |
Why?
|
| Retinol-Binding Proteins, Plasma | 2 | 2017 | 17 | 0.300 |
Why?
|
| alpha-2-HS-Glycoprotein | 2 | 2017 | 13 | 0.300 |
Why?
|
| Catheter Ablation | 1 | 2012 | 575 | 0.290 |
Why?
|
| Receptors, Leptin | 2 | 2017 | 67 | 0.290 |
Why?
|
| Fatty Acid-Binding Proteins | 2 | 2017 | 57 | 0.280 |
Why?
|
| Cholesterol, HDL | 3 | 2020 | 362 | 0.280 |
Why?
|
| Myocardium | 2 | 2012 | 1232 | 0.280 |
Why?
|
| Adiponectin | 2 | 2017 | 143 | 0.270 |
Why?
|
| Heart Diseases | 1 | 2012 | 724 | 0.270 |
Why?
|
| Carotid Intima-Media Thickness | 2 | 2023 | 83 | 0.260 |
Why?
|
| Leptin | 2 | 2017 | 306 | 0.250 |
Why?
|
| Pulmonary Artery | 1 | 2009 | 521 | 0.250 |
Why?
|
| Adult | 17 | 2023 | 82040 | 0.250 |
Why?
|
| Chi-Square Distribution | 3 | 2017 | 1312 | 0.250 |
Why?
|
| Heart Ventricles | 2 | 2009 | 847 | 0.240 |
Why?
|
| Diet | 2 | 2023 | 1477 | 0.230 |
Why?
|
| Cohort Studies | 6 | 2024 | 9470 | 0.220 |
Why?
|
| Facial Pain | 1 | 2003 | 20 | 0.220 |
Why?
|
| Child, Preschool | 7 | 2024 | 17061 | 0.220 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2009 | 587 | 0.220 |
Why?
|
| Environmental Pollutants | 1 | 2024 | 86 | 0.220 |
Why?
|
| Facial Paralysis | 1 | 2003 | 57 | 0.210 |
Why?
|
| Prospective Studies | 8 | 2019 | 13414 | 0.210 |
Why?
|
| Massachusetts | 3 | 2019 | 145 | 0.210 |
Why?
|
| Insulin | 2 | 2023 | 1483 | 0.200 |
Why?
|
| Amlodipine | 1 | 2021 | 24 | 0.200 |
Why?
|
| Migraine Disorders | 1 | 2003 | 84 | 0.200 |
Why?
|
| Longevity | 1 | 2023 | 155 | 0.200 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2024 | 205 | 0.200 |
Why?
|
| Masked Hypertension | 1 | 2021 | 1 | 0.200 |
Why?
|
| Boston | 4 | 2017 | 133 | 0.200 |
Why?
|
| White Coat Hypertension | 1 | 2021 | 10 | 0.200 |
Why?
|
| Odds Ratio | 2 | 2017 | 2311 | 0.190 |
Why?
|
| Angiopoietin-2 | 2 | 2012 | 36 | 0.190 |
Why?
|
| Receptor, TIE-2 | 2 | 2012 | 78 | 0.180 |
Why?
|
| Cost-Benefit Analysis | 2 | 2015 | 964 | 0.180 |
Why?
|
| Retrospective Studies | 7 | 2018 | 39890 | 0.180 |
Why?
|
| Regression Analysis | 2 | 2020 | 1571 | 0.170 |
Why?
|
| Risk Assessment | 5 | 2023 | 6764 | 0.170 |
Why?
|
| Age Factors | 6 | 2019 | 5457 | 0.170 |
Why?
|
| Logistic Models | 2 | 2017 | 3444 | 0.170 |
Why?
|
| Cardiovascular System | 1 | 2020 | 142 | 0.160 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2019 | 67 | 0.160 |
Why?
|
| Follow-Up Studies | 4 | 2018 | 15218 | 0.160 |
Why?
|
| Reference Values | 1 | 2020 | 1133 | 0.160 |
Why?
|
| Brazil | 1 | 2018 | 169 | 0.150 |
Why?
|
| Databases, Factual | 2 | 2016 | 2250 | 0.150 |
Why?
|
| Alanine Transaminase | 1 | 2019 | 239 | 0.150 |
Why?
|
| Healthy Volunteers | 1 | 2018 | 175 | 0.150 |
Why?
|
| Heredity | 1 | 2017 | 26 | 0.150 |
Why?
|
| Pulse | 1 | 2017 | 38 | 0.150 |
Why?
|
| Electric Impedance | 1 | 2017 | 101 | 0.140 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2021 | 260 | 0.140 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2019 | 201 | 0.140 |
Why?
|
| Coronary Disease | 3 | 2011 | 766 | 0.140 |
Why?
|
| Creatine Kinase | 1 | 2017 | 95 | 0.140 |
Why?
|
| Glucose | 1 | 2023 | 1218 | 0.140 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2017 | 1412 | 0.140 |
Why?
|
| Cholesterol, LDL | 2 | 2019 | 577 | 0.140 |
Why?
|
| Predictive Value of Tests | 2 | 2016 | 4960 | 0.140 |
Why?
|
| Middle Aged | 11 | 2017 | 90352 | 0.130 |
Why?
|
| Muscular Diseases | 1 | 2017 | 161 | 0.130 |
Why?
|
| Health Behavior | 2 | 2020 | 601 | 0.130 |
Why?
|
| Northern Territory | 1 | 2015 | 1 | 0.130 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2016 | 112 | 0.130 |
Why?
|
| Penicillin G Benzathine | 1 | 2015 | 19 | 0.120 |
Why?
|
| Rheumatic Fever | 1 | 2015 | 19 | 0.120 |
Why?
|
| Blood Glucose | 2 | 2017 | 1269 | 0.120 |
Why?
|
| Insurance Claim Review | 1 | 2015 | 73 | 0.120 |
Why?
|
| Endothelium, Vascular | 1 | 2019 | 879 | 0.120 |
Why?
|
| Benchmarking | 1 | 2016 | 275 | 0.120 |
Why?
|
| Area Under Curve | 1 | 2016 | 729 | 0.120 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2015 | 85 | 0.120 |
Why?
|
| Drug Recalls | 1 | 2013 | 4 | 0.120 |
Why?
|
| Patient Identification Systems | 1 | 2013 | 8 | 0.120 |
Why?
|
| Vascular Remodeling | 1 | 2014 | 49 | 0.110 |
Why?
|
| Demography | 1 | 2015 | 433 | 0.110 |
Why?
|
| Insurance, Health | 1 | 2016 | 261 | 0.110 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2015 | 236 | 0.110 |
Why?
|
| Drug Contamination | 1 | 2013 | 51 | 0.110 |
Why?
|
| Alcohol Drinking | 1 | 2017 | 600 | 0.110 |
Why?
|
| Heptanoic Acids | 1 | 2013 | 89 | 0.110 |
Why?
|
| Exercise | 1 | 2021 | 1184 | 0.110 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2015 | 216 | 0.110 |
Why?
|
| Pedigree | 1 | 2017 | 2042 | 0.110 |
Why?
|
| ROC Curve | 1 | 2016 | 1248 | 0.100 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2012 | 36 | 0.100 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2012 | 51 | 0.100 |
Why?
|
| Health Promotion | 1 | 2016 | 510 | 0.100 |
Why?
|
| Electrophysiology | 1 | 2012 | 350 | 0.100 |
Why?
|
| Coronary Artery Disease | 1 | 2019 | 884 | 0.100 |
Why?
|
| Blood Flow Velocity | 2 | 2012 | 541 | 0.100 |
Why?
|
| Recurrence | 2 | 2015 | 4878 | 0.100 |
Why?
|
| Heart Valve Prosthesis | 1 | 2015 | 306 | 0.100 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2012 | 156 | 0.100 |
Why?
|
| Risk Reduction Behavior | 1 | 2013 | 208 | 0.100 |
Why?
|
| Prognosis | 3 | 2019 | 22505 | 0.100 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2012 | 258 | 0.090 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2012 | 350 | 0.090 |
Why?
|
| Ambulatory Care | 1 | 2015 | 591 | 0.090 |
Why?
|
| Clinical Protocols | 1 | 2013 | 477 | 0.090 |
Why?
|
| Truncus Arteriosus | 1 | 2009 | 14 | 0.080 |
Why?
|
| Pyrroles | 1 | 2013 | 588 | 0.080 |
Why?
|
| Disease Progression | 1 | 2021 | 6867 | 0.080 |
Why?
|
| Linear Models | 1 | 2012 | 1093 | 0.080 |
Why?
|
| Fibrosis | 1 | 2012 | 733 | 0.080 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2012 | 631 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 1525 | 0.080 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2009 | 136 | 0.080 |
Why?
|
| Aging | 2 | 2010 | 1534 | 0.080 |
Why?
|
| Inflammation | 1 | 2018 | 2518 | 0.080 |
Why?
|
| Genotype | 1 | 2016 | 4252 | 0.070 |
Why?
|
| Tetralogy of Fallot | 1 | 2009 | 164 | 0.070 |
Why?
|
| Phenotype | 1 | 2019 | 6509 | 0.070 |
Why?
|
| Heart Atria | 1 | 2010 | 354 | 0.070 |
Why?
|
| Residence Characteristics | 1 | 2009 | 356 | 0.070 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2009 | 368 | 0.070 |
Why?
|
| Prosthesis Design | 1 | 2009 | 653 | 0.070 |
Why?
|
| Treatment Outcome | 2 | 2021 | 33737 | 0.070 |
Why?
|
| Ultrasonography | 1 | 2013 | 1933 | 0.070 |
Why?
|
| HIV Infections | 1 | 2018 | 2154 | 0.060 |
Why?
|
| Case-Control Studies | 1 | 2015 | 6224 | 0.060 |
Why?
|
| Reoperation | 1 | 2009 | 1392 | 0.060 |
Why?
|
| Time Factors | 2 | 2015 | 13006 | 0.060 |
Why?
|
| Aged | 4 | 2017 | 73333 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 5776 | 0.060 |
Why?
|
| Myocardial Infarction | 2 | 2002 | 1181 | 0.050 |
Why?
|
| Canada | 1 | 2023 | 440 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 3187 | 0.050 |
Why?
|
| Nutritional Status | 1 | 2023 | 353 | 0.050 |
Why?
|
| Latin America | 1 | 2021 | 127 | 0.050 |
Why?
|
| Overweight | 1 | 2023 | 484 | 0.040 |
Why?
|
| Private Sector | 1 | 2019 | 31 | 0.040 |
Why?
|
| Financing, Government | 1 | 2019 | 37 | 0.040 |
Why?
|
| Myocardial Reperfusion | 1 | 1999 | 101 | 0.040 |
Why?
|
| Liver Function Tests | 1 | 2019 | 185 | 0.040 |
Why?
|
| Ventricular Remodeling | 1 | 1999 | 188 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2023 | 699 | 0.040 |
Why?
|
| Serum | 1 | 2018 | 71 | 0.040 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2021 | 506 | 0.040 |
Why?
|
| Protein Precursors | 1 | 2018 | 249 | 0.030 |
Why?
|
| Troponin T | 1 | 2018 | 258 | 0.030 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2018 | 327 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 5101 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2018 | 558 | 0.030 |
Why?
|
| Critical Care | 1 | 2021 | 796 | 0.030 |
Why?
|
| Infant | 2 | 2021 | 13999 | 0.030 |
Why?
|
| Propensity Score | 1 | 2017 | 772 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2002 | 7100 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2016 | 505 | 0.030 |
Why?
|
| Health Status | 1 | 2016 | 631 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2021 | 5162 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 1939 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 1267 | 0.030 |
Why?
|
| Circadian Rhythm | 1 | 2014 | 332 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2023 | 5923 | 0.020 |
Why?
|
| Smoking Cessation | 1 | 2016 | 776 | 0.020 |
Why?
|
| Comorbidity | 1 | 2016 | 2394 | 0.020 |
Why?
|
| Cytokines | 1 | 2018 | 2825 | 0.020 |
Why?
|
| Heart Failure | 1 | 2002 | 2330 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2002 | 7381 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 2010 | 603 | 0.020 |
Why?
|
| Organ Size | 1 | 2010 | 692 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2021 | 8699 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 4372 | 0.020 |
Why?
|
| Smoking | 1 | 2016 | 2555 | 0.020 |
Why?
|
| Survival Rate | 2 | 2009 | 12541 | 0.010 |
Why?
|
| Atrial Fibrillation | 1 | 2010 | 730 | 0.010 |
Why?
|
| Captopril | 1 | 2002 | 36 | 0.010 |
Why?
|
| Heart Septum | 1 | 2002 | 60 | 0.010 |
Why?
|
| Ligation | 1 | 2002 | 206 | 0.010 |
Why?
|
| Cardiomegaly | 1 | 2002 | 180 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 6256 | 0.010 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2002 | 243 | 0.010 |
Why?
|
| Animals | 3 | 2016 | 61956 | 0.010 |
Why?
|
| Mice | 2 | 2002 | 35600 | 0.010 |
Why?
|